Boston, Massachusetts, United States
Candidates must possess a PhD or equivalent experience in protein biochemistry, molecular biology, biological engineering, or a related field. Proven expertise in protein analytics and protein-protein interactions using techniques such as BLI, SPR, ELISA, aSEC, DLS, and CE-SDS/cIEF is required. Proficiency in protein expression and characterization laboratory techniques, strong analytical and problem-solving skills, an adaptable and proactive mindset, and strong communication and collaboration skills are also necessary. Preferred qualifications include industry experience developing therapeutic antibodies, previous experience with brain shuttle technologies, background with protein mass spectrometry data, experience analyzing large datasets of protein-protein interactions, and familiarity with computational modeling of protein-protein interactions.
The Scientist/Sr. Scientist will drive projects to investigate binding kinetics of therapeutic proteins and generate/characterize individual binders for test article formulation. They will build pipelines to screen binders, analyze data, and generate plots for dissemination. Responsibilities include utilizing Manifold’s in vivo multiplexing capabilities to assess characterized molecules, generating, interpreting, and communicating high-quality data to inform program strategy, and collaborating cross-functionally to progress therapeutic programs. The role also involves maintaining clear documentation, sharing findings in team meetings, and contributing to strategic discussions on program direction and platform development.
Designs precision biologics using in vivo methods
Manifold Bio specializes in creating precision biologics for the pharmaceutical industry, focusing on drug design and development. Their main product is an in vivo drug design platform, which allows for testing drugs within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment, making it particularly effective for complex biologics. Unlike other companies, Manifold Bio's approach to drug design is distinct because it integrates in vivo testing with advanced protein multiplexing capabilities. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.